Avastin, also known as bevacizumab, is a monoclonal antibody developed by Genentech, a subsidiary of Roche.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

CC-91633 is a novel molecular glue drug that targets CK1α and falls within the therapeutic areas of neoplasms, hemic and lymphatic diseases.

Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

Bepirovirsen, developed by GSK in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the hepatitis B virus (HBV) RNA.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.

Daprodustat is a small molecule drug developed by GSK Plc which primarily targets Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) enzymes.

European Medicines Agency Approves Marketing Authorization Application for AVT05, a Biosimilar to Simponi® (golimumab).

Vutrisiran Sodium is a novel RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals.

Korro Bio has announced that it has submitted an application to the Bellberry HREC for a Phase 1/2 clinical trial of KRRO-110 targeting AATD.

AI-driven technological innovation not only enhances the targeting precision of siRNA but also paves new pathways for future gene therapies.

HuidaGene Therapeutics Secures FDA Approval for HG202, the First CRISPR/Cas13 RNA-Editing Treatment for Macular Degeneration.